The goal of this trial is to assess the impact of focal HIFU therapy on quality of life in patients with favourable intermediate-risk localised prostate cancer. The main question it aims to answer is:
What is the prostate cancer-related quality of life in patients with favourable intermediate-risk localised cancer treated by total prostatectomy or focal HIFU ?
Researchers will compare patients with favourable intermediate-risk localised cancer treated by total prostatectomy to patients with favourable intermediate-risk localised cancer treated by focal HIFU to see their quality of life.
Participants will answer EPIC-CP questionnaire 6 months, 12 months and 24 months after treatment
Patient, male, aged between ≥ 40 and ≤ 75 years
Patient with a life expectancy > 10 years at the time of inclusion.
Patient with a therapeutic strategy (prostatectomy or focal HIFU) defined during a PCR.
Patient with a diagnosis of localised prostate cancer at favourable intermediate risk
Patients with a contraindication to MRI
Stage T3a or b on MRI
Patient on long-term anticoagulants and unable to stop them.
Patient already included in another study